Full acquisition of Wilson Wolf's G-Rex bioreactor business is expected by the end of calendar 2027 or potentially earlier, integrating cell-therapy manufacturing hardware with Bio-Techne's reagents.
FDA Fast Track designations for two large cell-therapy customers are expected to accelerate commercial timelines, setting up later-stage GMP reagent demand.
COMET consumable pull-through is targeted to rise toward 90k per box per year over time as multiomic workflows are adopted.
Bio-Techne plans to launch ProximityScope, adding functional protein-protein interaction detection to its spatial biology portfolio.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Bio-Techne Corporation and 4,900+ companies.